ADMA · Adma Biologics, Inc.
$9.47
+0.06 (+0.64%)
At close · Aug 14
Market Cap
$2.12B
Shares
223.98M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Adam Grossman | President, Chief Executive Officer and Director | $10,237,326 |
| Kaitlin Kestenberg | Chief Operating Officer & Senior Vice President, Compliance | $3,488,647 |
| Brad L. Tade | Former Executive Vice President and Chief Financial Officer | $2,823,630 |
| Paul Terence Kohler | Current Chief Financial Officer and Treasurer | $2,296,949 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Adam Grossman | President, Chief Executive Officer and Director | $7,918,734 |
| Kaitlin Kestenberg | Chief Operating Officer & Senior Vice President of Compliance | $3,340,020 |
| Brad L. Tade | Chief Financial Officer and Treasurer | $2,936,435 |
| Paul Terence Kohler | Current Chief Financial Officer and Treasurer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Adam Grossman | Director, President, Chief Executive Officer and Interim Chief Financial Officer | $6,039,649 |
| Brian Lenz | Former Executive Vice President and Chief Financial Officer | $1,965,360 |
| Kaitlin Kestenberg | Chief Operating Officer & Senior Vice President of Compliance | — |
| Brad L. Tade | Chief Financial Officer and Treasurer | — |
| Paul Terence Kohler | Current Chief Financial Officer and Treasurer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Adam Grossman | Director, President, Chief Executive Officer and Interim Chief Financial Officer | $2,649,501 |
| Brian Lenz | Former Executive Vice President and Chief Financial Officer | $1,601,064 |
| Brad L. Tade | Chief Financial Officer and Treasurer | — |
| Kaitlin Kestenberg | Chief Operating Officer & Senior Vice President of Compliance | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Adam Grossman | Director, President and Chief Executive Officer | $4,361,250 |
| Brian Lenz | Executive Vice President and Chief Financial Officer | $2,366,680 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Adam Grossman | Director, President and Chief Executive Officer | $1,962,141 |
| Dr. James Mond | Former Executive Vice President, Chief Scientific Officer and Chief Medical Officer | $1,195,348 |
| Brian Lenz | Executive Vice President and Chief Financial Officer | $1,087,018 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Adam Grossman | Director, President and Chief Executive Officer | $1,702,022 |
| Dr. James Mond | Executive Vice President, Chief Scientific Officer and Chief Medical Officer | $1,237,422 |
| Brian Lenz | Executive Vice President and Chief Financial Officer | $1,122,154 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Adam Grossman | Director, President and Chief Executive Officer | $1,553,300 |
| Dr. James Mond | Executive Vice President, Chief Scientific Officer and Chief Medical Officer | $1,045,449 |
| Brian Lenz | Executive Vice President and Chief Financial Officer | $940,094 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Terry Kohler | Chief Financial Officer and Treasurer | Appointed | 2026-02-25 |
| Eduardo Rene Salas | Class I director | Appointed | 2025-01-02 |
| Steven A. Elms | member of the Company's Audit Committee | Appointed | 2024-11-21 |
| Alison C. Finger | member of the Company's Governance and Nominations Committee and Compensation Committee | Appointed | 2024-11-21 |
| Young T. Kwon, PhD | Chairman of the Company's Audit Committee | Appointed | 2024-11-21 |
| Bryant E. Fong | member of the Company's Board of Directors | Resigned | 2024-11-21 |
| Kaitlin Kestenberg | Chief Operating Officer and Senior Vice President, Compliance | Appointed | 2024-04-02 |
| Adam Grossman | Interim Chief Financial Officer | Appointed | 2024-02-28 |
| Alison C. Finger | Class I director | Appointed | 2023-10-02 |
Key facts
CIK
1368514
CUSIP
000899104
13F (30d)
292 filings
288 filers
Visit website
Investor relations